22
Jun
2017
Repare Secures $68M Series A to Discover ‘Synthetic Lethal’ Cancer Drugs
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account. 
Share:
9
Jun
2017
ASCO Takeaways A-Z (Part 2)
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
8
Jun
2017
ASCO Takeaways From A-Z (Part 1)
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
5
Jun
2017
ASCO Notebook: Observations on Cancer R&D from Foundation Medicine, Halozyme, Blueprint, Nektar
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
6
Apr
2017
AACR Reflections: Genomics Adapts to I-O World, Scientists Stand Up, and Re-Thinking How to Fight Early-Stage Cancer
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
30
Mar
2017
Third Rock’s Tango Gets $55M for CRISPR-Enabled Synthetic Lethal Cancer Combos
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
8
Mar
2017
Dunsire Joins Xtuit to Fight Microenvironment; Spero Gets $51.7M for Antibiotics
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
13
Feb
2017
Now More Than Ever: The Need for Personalized Medicine in Immuno-Oncology
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
5
Jan
2017
Neon Therapeutics Gets $70M to Push Neoantigen Cancer Vaccines
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
27
Sep
2016
Google Translate Star Leaves Venter’s Human Longevity to Join Illumina’s Grail
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
27
Jun
2016
The VP is Asking for Advice on Cancer. Share Yours Before I Go To Washington
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
19
May
2016
I-O: Who’s Doing What? (Part 2)
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
16
May
2016
Immuno-Oncology: Who’s Doing What?
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
10
Jan
2016
Illumina, Arch, Bezos, Gates Bet $100M on Deep Sequencing for Early Cancer Detection
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
8
Jan
2016
All the Biotech Deals and Financings You Can Grok Before JP Morgan 2016
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
21
Dec
2015
Which Biotechnologies Were Hyped, and Which Weren’t, in 2015
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
10
Nov
2015
Pursuing a Hard Cancer Target: Q&A With Warp Drive CEO Laurence Reid
This content is available for subscribers of Timmerman Report. Subscribe Now Sign in to your account.
Share:
2
Oct
2015
Fallout from the Drug Pricing Fiasco, the New Thing in Genome Editing & More
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
1
Oct
2015
The Next Macro (Phage) Thing in Immuno-Oncology
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
11
Sep
2015
Post-Labor Day Hangovers, Ipi-Nivo Combo Data & the PCSK9 Pricing Debate
This content is available for subscribers of the Timmerman Report. Subscribe Now
Share:
